What the research found
This is a personal n=1 self-experiment, not clinical research. The author injected a blend of BPC-157 and TB-500 (marketed as "Wolverine Blend") into the subcutaneous tissue near an injured distal biceps tendon over two months. The initial dose was 400 micrograms of each peptide nightly for a month, then doubled to 800 micrograms for a second month. Despite escalating the dose to rule out underdosing, the author reported no measurable improvement in elbow pain or function during pullups, rows, or bicep curls. No adverse effects were noted beyond the irritation that had prompted switching from an earlier formulation containing GHK-CU.
The author explicitly acknowledges the fundamental limitation: this negative outcome tells us nothing generalizable about peptide efficacy for tendon healing. Individual variation in injury type, tissue penetration, individual response, and the placebo effect mean that one person's failure to improve—or conversely, another person's dramatic improvement—cannot validate or refute the approach.
Why it matters for you
If you're considering BPC-157 or TB-500 for musculoskeletal injuries, this serves as a reminder that anecdotal improvement elsewhere doesn't predict your outcome. Many MyKine users explore peptides because they're eager to optimize recovery from training or manage chronic joint issues, and the appeal of a targeted injectable therapy is obvious. However, the lack of human dosing data means you're essentially guessing at effective concentrations, injection site, and treatment duration.
The other takeaway is more actionable: the author's experience with targeted physical therapy for a previous knee issue resolved what peptides did not. Stabiliser muscle activation and motor control—especially addressing supination weakness in distal biceps tendonitis—may deserve priority before or alongside peptide experiments. You can track this by noting when pain diminishes with specific movement patterns, something much easier to quantify than waiting for a peptide to work.
Caveats
- N=1 self-experiment — no control group, no blinding, high placebo and expectation bias
- No human dosing literature — the dose chosen was arbitrary, possibly subtherapeutic or excessive
- Self-reported outcome — pain and function were assessed by feel, not imaging or objective testing
- Unknown product quality — no verification of peptide identity, purity, or concentration
- Anecdotes elsewhere may be genuine — negative result here does not disprove efficacy in other individuals or injury types